Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26982392 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1GABRR1KDM4E | |
| SCHEMBL23099266 | 0.87 | MAPT (0.45) | ALDH1A1MAPTPTGS1GABRR1KDM4E | |
| SCHEMBL14702334 | 0.85 | GSR (0.45) | ALDH1A1MAPTPTGS1GABRR1KDM4E | |
| SCHEMBL9358019 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MAPTPTGS1SLC7A5LMNA | |
| SCHEMBL28705428 | 0.81 | PTGS1 (0.52) | ALDH1A1MAPTPTGS1GABRR1KDM4E | |
| SCHEMBL12655754 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTPTGS1KDM4EGSR | |
| SCHEMBL12655758 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1KDM4EGSR | |
| SCHEMBL20960490 | 0.78 | PTGS1 (0.54) | ALDH1A1MAPTPTGS1KDM4ESLC7A5 | |
| SCHEMBL12655753 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MAPTPTGS1SLC7A5GRIK1 | |
| SCHEMBL4956090 | 0.76 | PTGS1 (0.52) | ALDH1A1MAPTPTGS1KDM4ESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIB VZW (BE) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIP, MMP8, SLC11A2 | ALDH1A1 4565/4885MAPT 4028/4885PTGS1 908/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | ALDH1A1 4565/4885MAPT 4028/4885PTGS1 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.